Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Movers And Shakers In Biotech: Kite Pharma Inc (KITE) And Eleven Biotherapeutics Inc (EBIO)

It’s been a busy week in biotech so far, and the late start out of the US doesn’t seem to have had too much of an impact on volatility. As the week draws to a close, here are two of the biggest movers, one up one down – Kite Pharma Inc (NASDAQ:KITE) and Eleven Biotherapeutics Inc (NASDAQ:EBIO).

Eleven Biotherapeutics

Let’s kick things off with Eleven Biotherapeutics Inc (NASDAQ:EBIO). This Massachusetts based biotech closed out the session on Thursday at $1.96 a share. At Friday’s open, the company traded at $2.68, and at time of writing, comes in at $2.78 – a 42% gain. The upside comes as Eleven reported the effectiveness of its lead investigational new drug application (IND) for EBI-031, an experimental ocular disease candidate.

The drug is a humanized monoclonal antibody that is designed to bind what’s called interleukin-6 (IL-6). The science behind it isn’t all that complicated. IL-6 is a cytokine (which is just a type of small protein) that is responsible for the cell signaling process that induces inflammation. The ocular disease that Eleven is targeting with EBI-031 comes about as a result of inflammation at the surface of the eye, so (theoretically), through the binding of this cytokine, the cell signaling process doesn’t happen and the inflammation doesn’t occur. No inflammation, no ocular disease.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,

wavebreakmedia/Shutterstock.com

It’s not uncommon for this sort of announcement to serve up some upside in small cap biotech, but a close to 50% gain is a more active response than standard. Why is Eleven Biotherapeutics Inc (NASDAQ:EBIO) up so much, then?

Because the effectiveness of the IND, which basically just means the drug has the green light for clinical testing, triggers a milestone payment for Eleven. The company has a collaboration agreement with Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) that sees the two work together on the development of the drug, which at the top end will see Eleven pick up $262.5 million in milestone payments.

This first milestone payment totals $22.5 million – a number that amounted to circa two thirds of the company’s market capitalization pre-today’s gains. That’s why the market has responded in this fashion despite it being such early days for the drug, and the company, in question.

Follow Eleven Biotherapeutics Inc. (NASDAQ:EBIO)
Trade (NASDAQ:EBIO) Now!

Kite Pharma Inc

This one is a little more convoluted than the Eleven Biotherapeutics situation. At time of writing (mid morning session, US) Kite Pharma Inc (NASDAQ:KITE) is down nearly 10% on its Thursday close and looks set to lose further strength before the week draws to a close. This comes as the company announced it had completed its enrollment in its lead lymphoma trial, and that it expects to report top line and file for FDA approval before the year draws to a close. Ordinarily, this would serve up some positive sentiment. So why is the company down today? Well, Kite’s pipeline is primarily composed of a family of oncology drugs called CART therapies. We won’t go into too much detail about how these drugs work for the purposes of this discussion, but as a broad description, they are modified cells designed to induce an immune response to cancerous cells in cancer patients.

Anyway, another company that is working in the space, Juno Therapeutics Inc (NASDAQ:JUNO), just announced that the FDA has placed a clinical hold on its lead phase II CART candidate. Reportedly, three of the twenty patients in the trial have dies of what’s called cerebral edema, which is where fluid builds up in the brain and causes pressure. Juno itself is down nearly 30% at time of writing, and while the situation looks to be specific to a combination therapy of the company’s own candidate and an SOC chemotherapy drug, it’s had a collateral impact on the CART space as a whole. How long this impact will last remains to be seen – markets look to have sold off a little heavily on the situation, especially when considering companies like Kite Pharma Inc (NASDAQ:KITE) are suffering double digit losses, but it’s tough to gauge the overall impact. Chances are the sector will start to recover early next week as more details become clear.

Follow Kite Pharma Inc. (NASDAQ:KITE)
Trade (NASDAQ:KITE) Now!

Note: This article is written by Mark Collins and was originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!